Journal ArticleDOI
1.5 Efficacy and Safety of Dulaglutide vs. Metformin in Type 2 Diabetes (AWARD-3) (69-OR)
Guillermo E. Umpierrez,Federico Pérez Manghi,Santiago Tofe Povedano,Linda Shurzinske,Valeria Pechtner +4 more
- Vol. 11, Iss: 3, pp 78-78
Reads0
Chats0
TLDR
This Phase 3, randomized, double-blind, parallel-arm, monotherapy study compared the efficacy and safety of 2 doses of dulaglutide to metformin in patients with early type 2 diabetes treated with diet and exercise alone or in combination with 1 oral antidiabetic medication.Abstract:
This Phase 3, randomized, double-blind, parallel-arm, monotherapy study compared the efficacy and safety of 2 doses of dulaglutide (DU), a long-acting GLP-1-receptor agonist, to metformin (MET) in patients with early type 2 diabetes (mean 2.6 years) treated with diet and exercise alone or in combination with 1 oral antidiabetic medication (low dose for ≥ 3 months before screening).read more
Citations
More filters
Journal ArticleDOI
The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Jochen Seufert,Baptist Gallwitz +1 more
TL;DR: Early data suggest that GLP‐1RAs may also have the potential to favourably impact cardiovascular disease, obesity or neurological disorders in people without diabetes in the future.
Journal ArticleDOI
Novel Agents for the Treatment of Type 2 Diabetes
TL;DR: Novel therapeutic options that hold particular promise for type 2 diabetes management are examined, including early initiation of combination therapy using multiple drugs with different mechanisms of action.
Journal ArticleDOI
Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
Zachary Skrivanek,Brenda Gaydos,Jenny Y. Chien,Mary Jane Geiger,Michael Heathman,Scott M. Berry,James H. Anderson,T. Forst,Zvonko Milicevic,Donald Berry +9 more
TL;DR: An adaptive, seamless, double‐blind study comparing dulaglutide, a once‐weekly glucagon‐like peptide‐1 (GLP‐1) receptor agonist, with placebo at 26 weeks and sitagliptin up to 104 weeks, whose results are presented here.